Millenia Hope Biopharma, a Subsidiary of Millenia Hope Inc., Files its SB-2 Registration Statement
Millenia Hope Inc. (OTC BB: MLHP, FRANKFURT MLF) announced today that its subsidiary, Millenia Hope Pharmaceuticals (tradename: Millenia Hope Biopharma) has filed its SB-2 Registration Statement with the SEC, pursuant to becoming a public reporting company.
Montreal, Canada and Wilmington, DE (PRWEB) September 7, 2006 -- Millenia Hope Inc. (OTC BB: MLHP, FRANKFURT MLF) announced today that its subsidiary, Millenia Hope Pharmaceuticals (tradename: Millenia Hope Biopharma) has filed its SB-2 Registration Statement with the SEC, pursuant to becoming a public reporting company.
Leonard Stella, CEO and Chairman of Millenia Hope and Millenia Hope Biopharma, stated, ‘ This is another step forward in reaching the strategic goals for Millenia Hope and Millenia Hope Biopharma, to add future value for our shareholders.’
About Millenia Hope Biopharma
Millenia Hope Biopharma (MHB) is one of the world’s leading bioresearch firms in Phytomic Technologies, commercializing plant-cell based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. MHB has spent over $30 million in developing its unique Phytomics Technologies, including the world’s largest library of highly purified phytochemical fractions to be utilized by the pharmaceutical, cosmetic and nutraceutical industry. MHB is in the midst of the commercializing several projects with leading multi-national corporations.
About Millenia Hope
Millenia Hope develops innovative treatments and products that enhance the quality of life, has put in place programs to fight major infectious diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
Safe Harbor Statements:
Certain statements made in the release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Millenia Hope/Millenia Hope Biopharma that may be referred to as ‘ forward-looking statements’. Several important factors could cause actual results to differ materially from those in such forward-looking statements and Millenia Hope could encounter unanticipated obstacles and delays in developing products, services and markets.
For more information:
Please contact: Mr. Leonard Stella, CEO
Tel: (514) 846-5757 or laboratory (514) 288-8822
www.mh-b.com
# # #
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/WmV0YS1DcmFzLUVtcHQtWmV0YS1JbnNlLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
